155 related articles for article (PubMed ID: 35960849)
21. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.
Yan J; Li B; Lin B; Lee PT; Chung TH; Tan J; Bi C; Lee XT; Selvarajan V; Ng SB; Yang H; Yu Q; Chng WJ
Blood; 2016 Aug; 128(7):948-58. PubMed ID: 27297789
[TBL] [Abstract][Full Text] [Related]
22. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.
Corvetta D; Chayka O; Gherardi S; D'Acunto CW; Cantilena S; Valli E; Piotrowska I; Perini G; Sala A
J Biol Chem; 2013 Mar; 288(12):8332-8341. PubMed ID: 23362253
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.
Yan ZX; Wu LL; Xue K; Zhang QL; Guo Y; Romero M; Leboeuf C; Janin A; Chen SJ; Wang L; Zhao WL
Leukemia; 2014 Apr; 28(4):880-7. PubMed ID: 24104394
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma.
Cortes JR; Filip I; Albero R; Patiño-Galindo JA; Quinn SA; Lin WW; Laurent AP; Shih BB; Brown JA; Cooke AJ; Mackey A; Einson J; Zairis S; Rivas-Delgado A; Laginestra MA; Pileri S; Campo E; Bhagat G; Ferrando AA; Rabadan R; Palomero T
Cell Rep; 2022 Apr; 39(3):110695. PubMed ID: 35443168
[TBL] [Abstract][Full Text] [Related]
27. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
[TBL] [Abstract][Full Text] [Related]
29. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.
Tian X; Xu J; Dorfman DM
Am J Surg Pathol; 2019 Jan; 43(1):102-109. PubMed ID: 30371509
[TBL] [Abstract][Full Text] [Related]
30. EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia.
Kosalai ST; Morsy MHA; Papakonstantinou N; Mansouri L; Stavroyianni N; Kanduri C; Stamatopoulos K; Rosenquist R; Kanduri M
Epigenetics; 2019 Nov; 14(11):1125-1140. PubMed ID: 31216925
[TBL] [Abstract][Full Text] [Related]
31. The MYCN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
33. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
Zhang H; Qi J; Reyes JM; Li L; Rao PK; Li F; Lin CY; Perry JA; Lawlor MA; Federation A; De Raedt T; Li YY; Liu Y; Duarte MA; Zhang Y; Herter-Sprie GS; Kikuchi E; Carretero J; Perou CM; Reibel JB; Paulk J; Bronson RT; Watanabe H; Brainson CF; Kim CF; Hammerman PS; Brown M; Cichowski K; Long H; Bradner JE; Wong KK
Cancer Discov; 2016 Sep; 6(9):1006-21. PubMed ID: 27312177
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
36. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.
Jung M; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DD; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ
Cancer Res; 2017 Feb; 77(4):971-981. PubMed ID: 27923830
[TBL] [Abstract][Full Text] [Related]
37.
León TE; Rapoz-D'Silva T; Bertoli C; Rahman S; Magnussen M; Philip B; Farah N; Richardson SE; Ahrabi S; Guerra-Assunção JA; Gupta R; Nacheva EP; Henderson S; Herrero J; Linch DC; de Bruin RAM; Mansour MR
Cancer Discov; 2020 Jul; 10(7):998-1017. PubMed ID: 32349972
[TBL] [Abstract][Full Text] [Related]
38. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
39. MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells.
Zanotti S; Vanhauwaert S; Van Neste C; Olexiouk V; Van Laere J; Verschuuren M; Van der Meulen J; Mus LM; Durinck K; Tilleman L; Deforce D; Van Nieuwerburgh F; Hogarty MD; Decaesteker B; De Vos WH; Speleman F
Sci Rep; 2021 Jul; 11(1):14454. PubMed ID: 34262099
[TBL] [Abstract][Full Text] [Related]
40. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
